What's in Suzhou Suncadia Biopharmaceuticals Co., Ltd.'s pipeline?

Suzhou Suncadia Biopharmaceuticals Co., Ltd. has 45 drugs in our index: 1 marketed, 0 filed, 17 in Phase 3, 12 in Phase 2, 15 in Phase 1.

Which companies overlap with Suzhou Suncadia Biopharmaceuticals Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Merck Sharp & Dohme LLC, Asan Medical Center, Bristol-Myers Squibb, GERCOR - Multidisciplinary Oncology Cooperative Group.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/suzhou-suncadia-biopharmaceuticals-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Suzhou Suncadia Biopharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief

Suzhou Suncadia Biopharmaceuticals Co., Ltd. pipeline: 1 marketed, 0 filed, 17 Phase 3, 12 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 17 Phase 3 12 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fluorouracil Injection	Fluorouracil Injection	marketed	Antimetabolite	Thymidylate synthase	Oncology
Calcium Folinate Injection	Calcium Folinate Injection	phase 3	Folate analog / Chemotherapy adjunct	Folate metabolism pathway; dihydrofolate reductase substrate	Oncology
Gemcitabine and cisplatin / carboplatin	Gemcitabine and cisplatin / carboplatin	phase 3	Chemotherapy combination (nucleoside analog + platinum agent)		Oncology
Mitomycin for Injection	Mitomycin for Injection	phase 3	Antibiotic alkylating agent	DNA	Oncology
SHR-A1811 for Injection	SHR-A1811 for Injection	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor		Oncology
Hydroxycamptothecin for Injection	Hydroxycamptothecin for Injection	phase 3	Topoisomerase I inhibitor	Topoisomerase I	Oncology
SHR-1701、CAPOX	SHR-1701、CAPOX	phase 3	PD-L1 inhibitor (in combination with chemotherapy)	PD-L1	Oncology
SHR-A2102 and Adebrelimab	SHR-A2102 and Adebrelimab	phase 3	PD-1 inhibitor	PD-1	Oncology
SHR-A2009 ; Aumolertinib	SHR-A2009 ; Aumolertinib	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M	Oncology
tislelizumab, and platinum-based chemotherapy	tislelizumab, and platinum-based chemotherapy	phase 3
Epirubicin Hydrochloride for Injection	Epirubicin Hydrochloride for Injection	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA	Oncology
platinum-based dual-agent chemotherapy	platinum-based dual-agent chemotherapy	phase 3	Platinum-based chemotherapy combination		Oncology

Therapeutic area mix

Oncology · 18

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Asan Medical Center · 3 shared drug classes
Bristol-Myers Squibb · 3 shared drug classes
GERCOR - Multidisciplinary Oncology Cooperative Group · 3 shared drug classes
Janssen Research & Development, LLC · 3 shared drug classes
3D Medicines (Sichuan) Co., Ltd. · 3 shared drug classes
Shanghai Hengrui Pharmaceutical Co., Ltd. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Suzhou Suncadia Biopharmaceuticals Co., Ltd.:

Cite this brief

Drug Landscape (2026). Suzhou Suncadia Biopharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/suzhou-suncadia-biopharmaceuticals-co-ltd. Accessed 2026-05-16.